Study of new treatment plan for MAC lung infection
Part of Lungs & breathing clinical trials.
This study follows people with a newly diagnosed MAC lung infection (a specific type of mycobacterial disease) and tests how they do on the standard three-drug treatment plan. It may help researchers better understand outcomes and safety for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newly diagnosed MAC lung infection (or it came back) that needs a three-drug antibiotic regimen
- You can sign an informed consent form to join the study
- You are well enough overall that the study team feels it is safe for you to participate
- You do not have current drug or alcohol misuse that could affect safety or your ability to follow the study
- You do not have HIV infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a shorter course of antibiotics works for people with a specific type of lung infection caused by Mycobacterium avium complex (MAC). It aims to find a treatment that is just as effective but easier to complete.
This trial tests whether the drug Contezolid can quickly kill the bacteria that cause MAC lung disease, a type of lung infection. It is for people who have not been treated for this infection in the last 3 months.
This study looks at whether cordyceps sinensis, a natural fungus, can help prevent a lung infection caused by MAC bacteria from returning. If you have finished treatment for MAC lung disease and your sputum tests are negative, you may be able to join.
This trial studies how much medicine is needed (based on lab results) to treat MAC lung disease, an infection in the lungs. If you already have MAC and are receiving the recommended core antibiotics, your care may help researchers link treatment details to lab measurements.
This study tests an enhanced treatment strategy for MAC (Mycobacterium avium complex), a serious infection that can occur in people with HIV. The trial compares a new approach to standard treatment to see if it works better and is safer.
This study will look at people with a lung infection called nontuberculous mycobacterial lung disease to find out more about how their immune system reacts. If you have this condition, your medical history and possibly a lung sample can help researchers understand why some people get sicker than others.
Hear when a new Mycobacterium Avium Complex Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.